Lupin Ltd : Homegrown pharmaceutical major Lupin has delivered strong financial results. In the June 2024 quarter, Lupin reported a 16% year-on-year (YoY) revenue growth, reaching ₹ 55.1 billion. The company's US sales surged by 25% YoY to ₹ 19 billion, primarily driven by new product launches.